Prothioconazole


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0000080 Mitotic g1 phase Affects phenotype PMID:35048155
GO:0000084 Mitotic s phase Affects phenotype PMID:35048155
GO:0000085 Mitotic g2 phase Affects phenotype PMID:35048155
GO:0001843 Neural tube closure Decreases phenotype PMID:28263823
GO:0002072 Optic cup morphogenesis involved in camera-type eye development Decreases phenotype PMID:28263823
GO:0006915 Apoptotic process Increases phenotype PMID:35048155
GO:0008283 Cell population proliferation Increases phenotype PMID:25684042
GO:0016477 Cell migration Decreases phenotype PMID:35048155
GO:0044237 Cellular metabolic process Decreases phenotype PMID:35048155
GO:0048874 Host-mediated regulation of intestinal microbiota composition Affects phenotype PMID:36007749
GO:0055007 Cardiac muscle cell differentiation Decreases phenotype PMID:29337257
GO:0060037 Pharyngeal system development Decreases phenotype PMID:28263823
GO:0120189 Positive regulation of bile acid secretion Increases phenotype PMID:36007749
GO:1903047 Mitotic cell cycle process Affects phenotype PMID:35048155
GO:1904251 Regulation of bile acid metabolic process Increases phenotype PMID:36007749
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.